Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $6.92.
A number of research firms recently issued reports on CHRS. UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $4.00 to $1.50 in a research note on Friday, August 16th. Truist Financial lowered their target price on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Robert W. Baird lowered their target price on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Monday, July 1st. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Coherus BioSciences in a research note on Monday, August 5th. Finally, StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Friday, July 26th.
Check Out Our Latest Analysis on Coherus BioSciences
Hedge Funds Weigh In On Coherus BioSciences
Coherus BioSciences Stock Performance
NASDAQ CHRS opened at $1.25 on Wednesday. The business has a 50 day simple moving average of $1.54 and a 200 day simple moving average of $1.99. Coherus BioSciences has a 52-week low of $1.20 and a 52-week high of $5.47. The stock has a market cap of $143.41 million, a price-to-earnings ratio of -1.61 and a beta of 0.60.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Recommended Stories
- Five stocks we like better than Coherus BioSciences
- What Are the U.K. Market Holidays? How to Invest and Trade
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.